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Supplementary Table 1. Appraisal of Study Methodology  
 
Quality Criteria Maximum score 
Representation of the general diabetes population. Participants selected should be 
representative of the general diabetes population of a defined area, and methods 
of achieving this may involve using population registries, electoral roles, inhabitants 
of a defined area, or people registered with general practices of a defined area. 
Participants attending health checkups or respondents to health screening 
invitations may be biased and cover only certain population groups 
1 point 
Appropriate method of ascertaining diabetes population. Appropriate inclusion of all 
persons with diabetes is important for accurate DR prevalence estimates. This may 
be defined on the basis of a positive laboratory test (i.e. an oral glucose tolerance 
test or fasting blood glucose) and/or a self-reported history of physician’s diagnosis 
and current diabetes treatment. A review of medical records or use of a national 










Appropriate assessment of outcome. In this case, retinal photography must be 
performed on all study participants diagnosed with diabetes. Retinal photography 
should not be limited to participants who have been diagnosed with DR from a 
clinical examination for where photographs served only as documentation of 
clinical findings 
1 point 
Assessment of DR in both eyes. Studies that photographed only 1 randomly 
selected eye may miss detecting DR in the opposite eye 
2 points 
Number of retinal fields photographed 3 points 
Photographic based grading of DR and DME based on standardized protocols and 
definitions, such as the ETDRS, modified ETDRS, modified Airlie House, WESDR, 
AAO or EURODIAB classification schemes 
1 point 
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Supplementary Table 2. Characteristics of Included Study Populations 
 
Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; DR, diabetic retinopathy; FBG, fasting blood glucose; Hx, hi
NR, not reported; OGTT, oral glucose tolerance test; RBG, random blood glucose; SR, self-report, which includes self-reported history of physician diagnosis 
or use of diabetes medications; Tx, treatment; 2hBG, 2-hour post-load blood glucose. ADDITION, Anglo-Danish-Dutch study of Intensive Treatment in 
People with Screen-detected Diabetes in Primary Care; ARIC, Atherosclerosis Risk in Communities Study; Andhra Pradesh, Andhra Pradesh Eye Disease 
story; MR, medical records; 
Study Study Design DM  diagnosis DR data provided DME data provided Methodology score 
ADDITION DM study OGTT 2 eyes; 5 severity categories 2 eyes 9 
ARIC CVD study FBG/RBG/ SR 1 eye; modified ETDRS  1 eye 8 
Aarhus DM study Registry 2 eyes; 5 severity categories 2 eyes 9 
Andhra Pradesh Eye study SR 1 eye; 5 severity categories 2 eyes 6 
AusDiab DM study OGTT/SR 2 eyes; 5 severity categories 2 eyes 10 
BDES Eye study SR/RBG/HbA1C 2 eyes; modified ETDRS  2 eyes 11 
BES Eye study SR 2 eyes; yes/no No data 7 
BMES Eye study FBG/SR 2 eyes; ETDRS scale 2 eyes 10 
Beijing Eye study FBG/SR 1 eye; ETDRS scale 1 eye 10 
CHS CVD study FBG/SR  1 eye; ETDRS scale 1 eye 8 
CURES E.S. Eye study SR/2hBG Worse eye; 5 severity categories 1 eye 10 
EDC DM study MR 2 eyes; non-standard severity categories  1 eye 10 
EUREYE Eye study SR 2 eyes; yes/no  No data 7 
Funagata Eye study OGTT/SR 1 eye; ETDRS scale 1 eye 8 
Fyn DM study Registry 2 eyes; ETDRS scale 2 eyes 11 
Handan Eye study FBG/SR  2 eyes; ETDRS scale 2 eyes 10 
Hisayama Eye study OGTT/SR 2 eyes; non-standard severity categories  No data 9 
Hoorn DM study OGTT/SR 2 eyes; non-standard severity categories  2 eyes 10 
LALES Eye study SR/ HbA1C/ RBG 1 eye; non-standard severity categories  1 eye 11 
MESA CVD study FBG/SR 2 eyes; ETDRS scale 2 eyes 8 
MVIP Eye study SR 1 eye; yes/no 2 eyes 8 
NHANES National survey SR/ HbA1C Worse eye; modified ETDRS  2 eyes 9 
New Jersey 725 DM study MR 1 eye; modified ETDRS  1 eye 11 
Proyecto VER Eye study SR/ HbA1C Worst eye; modified ETDRS 1 eye 9 
Rotterdam Eye study SR/RBG/ 2hBG 2 eye; yes/no No data 8 
SINDI Eye study RBG/SR 1 eye; yes/no 2 eyes 10 
SNDREAMS DR study SR/ FBG 1 eye; 5 severity categories 1 eye 11 
Samutsakhon DM study SR, HbA1C Worse eye; non-standard severity categories  No data 9 
San Antonio  CVD study OGTT, SR 1 eye; non-standard severity categories  No data 11 
San Luis Valley DM study OGTT , SR Worse eye; modified ETDRS 1 eye 9 
Shihpai Eye study SR Worse eye; 5 severity categories 1 eye 8 
SiMES Eye study RBG, SR 2 eyes; 5 severity categories 2 eyes 10 
Turin DM study MR, registry  1 eye; non-standard severity categories  1 eye 10 
UKADS DM study MR 1 eye; non-standard severity categories  1 eye 9 
WESDR DR study MR Worse eye; 5 severity categories 1 eye 11 
 ©2012 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1909/-/DC1
SUPPLEMENTARY DATA 
 
Study; AusDiab, Australian Diabetes, Obesity and Lifestyle Study; BDES, Beaver Dam Eye Study; BES, Baltimore Eye Survey; BMES. Blue Mountains Eye 
Study; Beijing, Beijing Eye Study; CHS, Cardiovascular Health Study; CURES ES, Chennai Urban Rural Epidemiology Study (Eye Study); EDC, Pittsburgh 
Epidemiology of Diabetes Complications Study; EUREYE; European Eye Study; Funagata, Funagata Study; Handan, Handan Eye Study; Hisayama, 
Hisayama Study; Hoorn, Hoorn Study; LALES, Los Angeles Latino Eye Study; MESA, Multi-ethnic Study of Atherosclerosis; MVIP, Melbourne Vision 
Impairment Project; NHANES, National Health and Nutrition Examination Survery; Proyect VER, Proyecto Vision and Eye Research;Rotterdam, Rotterdam 
Study; SiMES, Singapore Malay Eye Study; SINDI, Singapore Indian Eye Study; SNDREAMS, Sankara Nethralaya Diabetic Retinopathy Epidemiology and 
Molecular Genetics Study; UKADS, UK Asian Diabetes Study; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy. 
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Supplementary Table 3. Age-Standardized Prevalence of Diabetic Retinopathy by Study in Diabetic Subjects Aged 20 to 79 years 
 
   Any DR PDR DME VTDR Age-Standardised Prevalence per 100 (95% CI) 


















(DR) Any DR PDR DME VTDR 
By Study               
Aarhus Both 2 206 50 205 4 205 5 206 8 24.71 (23.08, 26.34) 1.58 (1.33, 1.84) 2.26 (1.94, 2.59) 3.14 (2.78, 3.5) 
ADDITION Both 2 534 61 534 0 533 5 534 5 9.53 (9.12, 9.95) 0 (0, 0.66) 0.91 (0.77, 1.04) 0.9 (0.77, 1.04) 
AndhraPradesh One 2 203 36 203 0 203 5 203 5 15.7 (14.91, 16.49) 0 (0, 1.72) 2.21 (1.91, 2.51) 2.21 (1.91, 2.51) 
ARIC One 1 1652 276 1550 14 1609 10 1652 23 14.13 (13.87, 14.39) 0.84 (0.78, 0.91) 0.54 (0.49, 0.59) 1.27 (1.19, 1.35) 
AusDiab Both 2 723 106 723 12 722 16 723 21 13.92 (13.33, 14.51) 1.78 (1.52, 2.04) 2.43 (2.08, 2.78) 3.04 (2.69, 3.4) 
BDES Both 3 454 146 454 8 451 13 454 19 25.64 (24.94, 26.35) 1.18 (1.04, 1.32) 2.22 (2.01, 2.42) 3.14 (2.9, 3.38) 
Beijing One 2 345 96 345 15 345 10 345 20 22.44 (21.66, 23.21) 3.53 (3.23, 3.84) 3.04 (2.73, 3.35) 4.91 (4.54, 5.27) 
BES Both 2 461 116 NR NR NR NR NA NA 21.8 (21.19, 22.41) † NR NR NA 
BMES Both 6 244 62 243 4 244 12 244 15 22.71 (21.63, 23.79) 1.49 (1.21, 1.77) 4.46 (3.98, 4.95) 5.75 (5.2, 6.31) 
CHS One 1 247 41 221 6 243 5 247 8 6.32 (6, 6.63) 1.03 (0.9, 1.17) 0.78 (0.67, 0.89) 1.23 (1.09, 1.37) 
CURES E.S. Worse 4 1707 302 1707 16 1707 90 1707 106 17.69 (17.34, 18.04) 1.03 (0.94, 1.12) 5.14 (4.96, 5.33) 6.17 (5.97, 6.38) 
EDC Both 3 547 514 537 196 547 127 547 225 59.91 (57.89, 61.93) 32.37 (30.8, 33.94) 15.19 (14.17, 16.21) 35.63 (34.01, 37.25) 
EUREYE Both 2 559 109 NR NR NR NR NA NA 7.42 (7.19, 7.65) † NR NR NA 
Funagata One 1 156 22 156 5 154 0 156 5 12.31 (11.38, 13.23) 2.5 (2.1, 2.89) 0 (0, 2.27) 2.5 (2.1, 2.89) 
Fyn Both 9 192 186 192 96 189 15 192 101 97.24 (92.97, 101.51) 49.68 (46.66, 52.7) 10.35 (8.35, 12.35) 52.06 (49.02, 55.1) 
Handan Both 2 366 98 366 6 183 20 366 21 25.04 (24.08, 26) 2.14 (1.65, 2.62) 11.7 (10.27, 13.14) 5.76 (5.2, 6.32) 
Hisayama Both 1 274 43 274 5 NR NR NA NA 13.06 (12.36, 13.75) † 0.95 (0.81, 1.08) NR NA 
Hoorn Both 2 125 30 125 1 NR NR NA NA 19.64 (18.28, 20.99) † 0.39 (0.26, 0.51)* NR NA 
LALES One 7 1190 562 1188 73 1183 126 1190 167 40.03 (39.51, 40.54)* 5.25 (5.07, 5.44) 8.99 (8.75, 9.24) 11.91 (11.63, 12.19) 
MESA Both 2 850 216 849 20 828 67 850 76 22.64 (22.14, 23.15) 1.96 (1.82, 2.11) 6.81 (6.53, 7.08) 7.59 (7.3, 7.88) 
MVIP Both 2 211 60 211 9 211 14 211 18 24.55 (23.48, 25.61) 4.71 (4.21, 5.22) 5.04 (4.58, 5.5) 7.99 (7.36, 8.61) 
NewJersey725 One 7 355 253 348 46 355 48 355 75 54.44 (52.74, 56.15) 16.88 (15.88, 17.88) 14.58 (13.66, 15.49) 25.92 (24.69, 27.15) 
NHANES Worse 2 937 268 937 22 935 35 937 54 24.14 (23.68, 24.59) 1.83 (1.7, 1.95) 3.25 (3.08, 3.42) 4.76 (4.56, 4.96) 
ProyectoVER One 3 885 424 883 57 875 66 885 102 40.14 (39.54, 40.73) 5.35 (5.14, 5.57) 6.4 (6.16, 6.64) 9.68 (9.39, 9.97) 
Rotterdam Both 2 486 76 NR NR NR NR NA NA 13.91 (13.11, 14.72) † NR NR NA 
SAHS One 7 381 153 381 16 NR NR NA NA 38.31 (37.29, 39.32) † 3.96 (3.65, 4.26) NR NA 
Samutsakhon One 7 96 11 96 3 NR NR NA NA 10.02 (9.1, 10.93) † 2.43 (1.98, 2.87) NR NA 
SanLuisValley Worse 3 392 129 389 17 368 11 392 23 33.64 (32.44, 34.83) 4.3 (3.92, 4.69) 2.74 (2.49, 2.99) 5.66 (5.24, 6.09) 
Shihpai Worse 2 139 18 139 3 139 7 139 10 4.93 (4.56, 5.3) 0.82 (0.67, 0.97) 1.92 (1.69, 2.15) 2.74 (2.46, 3.01) 
SiMES Both 2 757 268 NR NR 757 44 NA NA 29.47 (28.9, 30.03) NR 4.69 (4.46, 4.91) NA 
SINDI One 2 1075 163 NR NR 1075 44 NA NA 12 (11.71, 12.29) NR 3.57 (3.41, 3.74) NA 
SNDREAMS One 4 1393 261 1393 21 1393 46 1393 59 15.95 (15.65, 16.26) 1.33 (1.24, 1.42) 2.82 (2.7, 2.95) 3.67 (3.52, 3.82) 
Turin One 2 310 131 310 9 310 24 310 33 69.13 (56.97, 81.3) 3.74 (3.24, 4.24) 5.46 (4.89, 6.02)* 9.2 (8.44, 9.96) 
UKADS One 2 910 369 910 127 910 94 910 127 39.74 (38.61, 40.87) 13.96 (13.24, 14.68) 10.38 (9.78, 10.98) 13.96 (13.24, 14.68) 
WESDR Worse 7 1930 1292 1930 331 1577 212 1930 427 66.59 (65.94, 67.24) 18.01 (17.67, 18.36) 14.21 (13.88, 14.54) 23.35 (22.96, 23.74) 
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Abbreviations:  DME: Diabetic Macular Edema; DR: Diabetic Retinopathy;  NR: Not reported;  NA: Not applicable;  PDR: Proliferative Diabetic Retinopathy; 
VTDR: Vision-threatening Diabetic Retinopathy. ADDITION, Anglo-Danish-Dutch study of Intensive Treatment in People with Screen-detected Diabetes in 
Primary Care; ARIC, Atherosclerosis Risk in Communities Study; Andhra Pradesh, Andhra Pradesh Eye Disease Study; AusDiab, Australian Diabetes, 
Obesity and Lifestyle Study; BDES, Beaver Dam Eye Study; BES, Baltimore Eye Survey; BMES. Blue Mountains Eye Study; Beijing, Beijing Eye Study; 
CHS, Cardiovascular Health Study; CURES ES, Chennai Urban Rural Epidemiology Study (Eye Study); EDC, Pittsburgh Epidemiology of Diabetes 
Complications Study; EUREYE; European Eye Study; Funagata, Funagata Study; Handan, Handan Eye Study; Hisayama, Hisayama Study; Hoorn, Hoorn 
Study; LALES, Los Angeles Latino Eye Study; MESA, Multi-ethnic Study of Atherosclerosis; MVIP, Melbourne Vision Impairment Project; NHANES, National 
Health and Nutrition Examination Survery; Proyect VER, Proyecto Vision and Eye Research;Rotterdam, Rotterdam Study; SiMES, Singapore Malay Eye 
Study; SINDI, Singapore Indian Eye Study; SNDREAMS, Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study; UKADS, 
UK Asian Diabetes Study; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy. 
 
† Our ‘any DR’ definition includes DME information.  Studies that did not provide DME data (BES, EUREYE, Hisayama, Hoorn, Rotterdam, SAHS and 
Samutsakhon) may have higherprevalence estimates for any DR than that reported here.  
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